Compound K, a Ginsenoside Metabolite, Inhibits Colon Cancer Growth via Multiple Pathways Including p53-p21 Interactions.docVIP

下载本文档

8
0
约4.34万字
约 16页
2017-05-08 发布于上海
举报
版权申诉

Compound K, a Ginsenoside Metabolite, Inhibits Colon Cancer Growth via Multiple Pathways Including p53-p21 Interactions.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Compound K, a Ginsenoside Metabolite, Inhibits Colon Cancer Growth via Multiple Pathways Including p53-p21 Interactions

Int. J. Mol. Sci. 2013, 14, 2980-2995; doi:10.3390/ijmOPEN ACCESS International Journal of Molecular Sciences ISSN 1422-0067 /journal/ijms Article Compound K, a Ginsenoside Metabolite, Inhibits Colon Cancer Growth via Multiple Pathways Including p53-p21 Interactions Zhiyu Zhang , Guang-Jian Du , Chong-Zhi Wang 1,2, Xiao-Dong Wen , Tyler Calway 2, 1,2 1,2 1,2 Zejuan Li , Tong-Chuan He , Wei Du , Marc Bissonnette , Mark W. Musch 6, 3 4 5 6 6 Eugene B. Chang and Chun-Su Yuan 1,2,7,* 1 Tang Center for Herbal Medicine Research, Pritzker School of Medicine, University of Chicago, 5841 S. Maryland Ave., MC 4028, Chicago, IL 60637, USA; E-Mails: zhiyu@ (Z.Z.); gdu@ (G.-J.D.); cwang@ (C.-Z.W.); cpuwxd@ (X.-D.W.) 2 Department of Anesthesia Critical Care, Pritzker School of Medicine, University of Chicago, 5841 S. Maryland Ave., MC 4028, Chicago, IL 60637, USA; E-Mail: tyler.calway@ 3 Section of Hematology/Oncology, Pritzker School of Medicine, University of Chicago, 5841 S. Maryland Ave., MC 4028, Chicago, IL 60637, USA; E-Mail: zjli@ 4 Department of Orthopaedic Surgery, Pritzker School of Medicine, University of Chicago, 5841 S. Maryland Ave., MC 3079, Chicago, IL 60637, USA; E-Mail: tche@ 5 Ben May Department for Cancer Research, Pritzker School of Medicine, University of Chicago, 5841 S. Maryland Ave., MC 4028, Chicago, IL 60637, USA; E-Mail: wei@ 6 Department of Medicine, University of Chicago, 900 E. 57th street, MB 9, Chicago, IL 60637, USA; E-Mails: mbissonn@ (M.B.); mmusch@ (M.W.M.); echang@ (E.B.C.) 7 Committee on Clinical Pharmacology and Pharmacogenomics, Pritzker School of Medicine, University of Chicago, 5841 S. Maryland Ave., MC 4028, Chicago, IL 60637, USA * Author to whom correspondence should be addressed; E-Mail: cyuan@; Tel.: +1-773-702-1916; Fax: +1-773-834-0601. Received: 6 December 2012; in revised form: 24 January 2013 / Accepted: 25 January 2013 / Published: 31 January 2013 Abstract: Compound K (20-O-beta-D-gluco